Silverback Therapeutics (NASDAQ:SBTX) Stock Price Down 1% - Here's What Happened

Key Points

• Shares fell 1% in mid-day trading to last trade $8.17 after touching $8.09, with volume of 3,317,633 shares—an 882% increase versus the average session volume of 337,931.
• Silverback is a clinical-stage biotech developing next-generation immunotherapies via its proprietary ImmunoTAC™ platform, which conjugates toll-like receptor agonists to tumor-targeting antibodies; its pipeline includes multiple early-phase antibody-TLR agonist conjugates.
• The company has a market cap of $294.59 million, a negative P/E of -3.38, a beta of 0.60, and 50-/200-day moving averages of $9.53 and $9.79, respectively.

Silverback Therapeutics, Inc. (NASDAQ:SBTX - Get Free Report) shares fell 1% during mid-day trading on Tuesday . The company traded as low as $8.09 and last traded at $8.17. 3,317,633 shares were traded during mid-day trading, an increase of 882% from the average session volume of 337,931 shares. The stock had previously closed at $8.25.

Silverback Therapeutics Price Performance

The firm has a market cap of $294.59 million, a price-to-earnings ratio of -3.38 and a beta of 0.60. The business's 50-day moving average price is $9.53 and its two-hundred day moving average price is $9.79.

Silverback Therapeutics Company Profile

Silverback Therapeutics, Inc NASDAQ: SBTX is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company's proprietary ImmunoTAC™ (tumor-activated cytokine) platform is designed to harness the innate immune system by conjugating toll-like receptor agonists to tumor-targeting antibodies. This modular approach aims to deliver immune-activating molecules directly to the tumor microenvironment, potentially improving the safety and efficacy profiles of existing immunomodulatory therapies.

Silverback's pipeline includes multiple antibody-TLR agonist conjugates in early-phase clinical trials, each directed against distinct tumor-associated antigens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.